OTCMKTS:CTDH - CTD Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.8140 -0.01 (-1.21 %)
(As of 01/21/2019 04:00 PM ET)
Previous Close$0.82
Today's Range$0.70 - $0.82
52-Week Range$0.25 - $1.18
Volume7,915 shs
Average Volume2,366 shs
Market Capitalization$71.10 million
P/E RatioN/A
Dividend YieldN/A
CTD Holdings, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Neimann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. CTD Holdings, Inc. was founded in 1990 and is based in Gainesville, Florida.

Receive CTDH News and Ratings via Email

Sign-up to receive the latest news and ratings for CTDH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Industrial organic chemicals
SectorBasic Materials
Current SymbolOTCMKTS:CTDH



Sales & Book Value

Annual Sales$1.24 million
Book Value$0.02 per share


Net Income$-3,830,000.00
Net Margins-454.09%


Market Cap$71.10 million
OptionableNot Optionable

CTD (OTCMKTS:CTDH) Frequently Asked Questions

What is CTD's stock symbol?

CTD trades on the OTCMKTS under the ticker symbol "CTDH."

When is CTD's next earnings date?

CTD is scheduled to release their next quarterly earnings announcement on Monday, April 15th 2019. View Earnings Estimates for CTD.

Has CTD been receiving favorable news coverage?

News articles about CTDH stock have been trending very positive this week, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. CTD earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are some of CTD's key competitors?

Who are CTD's key executives?

CTD's management team includes the folowing people:
  • Mr. N. Scott Fine, Chairman & CEO (Age 61)
  • Dr. Jeffrey L. Tate, COO, Chief Scientific Officer & Director (Age 60)
  • Mr. George L. Fails, Exec. VP and Operations Mang. (Age 73)
  • Dr. Sharon H. Hrynkow, Sr. VP of Medical Affairs & Member of Scientific Advisory Board (Age 58)
  • Kevin J. Strattan, VP of Fin. & Compensation

How do I buy shares of CTD?

Shares of CTDH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CTD's stock price today?

One share of CTDH stock can currently be purchased for approximately $0.8140.

How big of a company is CTD?

CTD has a market capitalization of $71.10 million and generates $1.24 million in revenue each year. CTD employs 4 workers across the globe.

What is CTD's official website?

The official website for CTD is http://www.admabiologics.com.

How can I contact CTD?

CTD's mailing address is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. The biotechnology company can be reached via phone at 386-418-8060.

MarketBeat Community Rating for CTD (OTCMKTS CTDH)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  37 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  85
MarketBeat's community ratings are surveys of what our community members think about CTD and other stocks. Vote "Outperform" if you believe CTDH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTDH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel